COMP <GO>
ZJYL vs JNJ // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
JIN MEDICAL INTERNATIONAL LTD. (Class A) (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ZJYL 0
— JNJ 9
■ METRIC PARITY
LAST: $2.35 (+26.34%) • MKT CAP: $294.2M
options-implied-move
—
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZJYL VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZJYL | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 29.20% | 67.90% | -38.70 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | 25.50% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 47.1x | 18.5x | +28.60 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | -1.27% | 2.97% | -4.24 | JNJ | /fcf-yield <GO> |
| Operating Margin | 2.90% | 34.70% | -31.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 5.80% | 28.50% | -22.70 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -12.00% | 6.00% | -18.00 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.59 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.3 | 62.1 | -17.80 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $294.2M | $662.49B | -$662.20B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZJYL REV | JNJ REV | ZJYL GROSS % | JNJ GROSS % | ZJYL FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $20.7M | $94.19B | 29.2% | 67.9% | -$3.7M | $19.70B |
| FY 2024 | $23.5M | $88.82B | 40.4% | 69.1% | -$1.4M | $19.84B |
| FY 2023 | $19.8M | $85.16B | — | — | $3.1M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZJYL // BETA —
JNJ // BETA 1.08